Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)

Launched by SPUR THERAPEUTICS · Aug 6, 2024

Keywords

ClinConnect Summary

This clinical trial, called GALILEO-2, is looking at the long-term effects of a treatment called FLT201 in people with Type 1 Gaucher disease. If you or a loved one participated in a previous trial where FLT201 was given, this study may be of interest. It involves following participants for five years after they received the treatment to see how they are doing over time.

To be eligible for this trial, participants must have previously received FLT201 and should be able to give informed consent, meaning they understand the study and agree to participate. There are no specific exclusions, so if you meet the criteria, you can join. Throughout the study, participants will have regular check-ins to monitor their health and any changes that may occur after treatment. This long-term follow-up aims to gather important information about the lasting effects of FLT201 on individuals with Gaucher disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants who have previously received FLT201 (including those who may have required recommencement or initiation of ERT/substrate reduction therapy \[SRT\]).
• • 2. Participants able to give full informed consent and able to comply with all requirements of the trial.
• Exclusion Criteria:
• • n/a